This Phase III trial is comparing the effects of giving an oral drug (Osimertinib) alone and in combination with stereotactic radiosurgery (SRS) in patients with non-small cell lung cancer (NSCLC) that has spread to the brain.
This trial is treating patients with non-small cell lung cancer (NSCLC).
This is a systemic therapy and radiotherapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Randomised Phase II Trial of Osimertinib With or Without Stereotactic Radiosurgery for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
Trans Tasman Radiation Oncology Group (TROG)
In this trial, patients with EGFR mutated non-small cell lung cancer (NSCLC) will be randomised to receive oral Osimernib (80mg, taken once daily) alone or following upfront stereotactic radiosurgery (SRS).
Recruiting Hospitals Read More